Vertex Pharmaceuticals (VRTX) Cost of Revenue (2009 - 2026)

Vertex Pharmaceuticals' Cost of Revenue history runs 18 years deep, the most recent figure standing at $392.8 million for Q1 2026.

• On a quarterly basis, Cost of Revenue rose 8.21% year-over-year to $392.8 million in Q1 2026; TTM through Mar 2026 was $1.7 billion, a 8.4% increase from a year earlier, with the FY2025 full-year figure at $1.7 billion, up 7.89% from the prior year.
• Cost of Revenue slipped to $392.8 million in Q1 2026 per VRTX's latest filing, from $466.0 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $466.0 million in Q4 2025 and bottomed at $245.8 million in Q1 2022.
• The 5-year median for Cost of Revenue is $363.0 million (2025), against an average of $348.1 million.
• Across the five-year window, Cost of Revenue gained 29.9% in 2023 and grew 5.65% in 2025, its largest moves.
• Year by year, Cost of Revenue stood at $283.3 million in 2022, then climbed by 29.9% to $368.0 million in 2023, then grew by 15.05% to $423.4 million in 2024, then gained by 10.06% to $466.0 million in 2025, then decreased by 15.71% to $392.8 million in 2026.
• Per Business Quant, the three latest VRTX Cost of Revenue figures stand at $392.8 million (Q1 2026), $466.0 million (Q4 2025), and $414.8 million (Q3 2025).